Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its pipeline of novel immunomodulatory drug candidates. Bioniz Therapeutics, which is based in Irvine, California, is a clinical-stage biopharma company focused on developing precision cytokine targeted therapies for treating immuno-inflammatory diseases. […]
Bioniz Therapeutics has secured orphan drug designation for BNZ-1 from the European Commission (EC) for the treatment of cutaneous T-cell lymphoma (CTCL), a rare type of skin cancer. Previously, BNZ-1 was given orphan drug designation by the US Food and Drug Administration (FDA). Recently, Bioniz Therapeutics wrapped up a phase 2 study of BNZ-1 in […]
Bioniz Therapeutics has announced positive data from a phase 1/2 clinical trial of BNZ-1 for the treatment of relapsed or refractory cutaneous T-cell lymphoma (rCTCL). BNZ-1 is an immuno-modulator drug candidate. It is a multi-cytokine inhibitor of three interleukins, that includes IL-2, IL-9, and IL-15. It is the lead asset from Bioniz Therapeutics’ platform of […]